View Post

HUNDREDS of cancer victims given hope as drug ‘cure’ is fast-tracked

In In The News by Barbara Jacoby

By: Lucy Johnston From: express.co.uk A REVOLUTIONARY cancer drug expected to save hundreds of lives a year has been deemed so effective that the Government has bypassed red tape to make it available on the NHS immediately. From tomorrow patients with advanced kidney cancer will be able to access the landmark drug nivolumab.The treatment has not yet been given a …

View Post

Breakthrough cancer drug unlike anything else on the market

In In The News by Barbara Jacoby

rainli,By: Alicia Neaves From: kens5.com A new drug used right here in San Antonio could change the way we treat brain, kidney and liver cancer. Inventors are working to eliminate the side effects of chemotherapy, and make this new, breakthrough drug the first treatment a cancer patient will get. It’s called Mipsagargin. Right now, it’s finishing up phase 2 of …

View Post

The FDA is quickly giving this cancer drug approval for new uses

In In The News by Barbara Jacoby

By: Lydia Ramsey From: businessinsider.my Bristol-Myers Squibb received two Food and Drug Administration approvals in two days, to expand the use of a new type of cancer treatment. On Monday, the FDA approved Opdivo to treat a type of kidney cancer. The next day, the agency gave the nod for the same drug to be used to treat an advanced …

View Post

Two Kidney Cancer Drugs Show Promise in Separate Studies

In In The News by Barbara Jacoby

By: Ron Winslow From: wsj.com Two drugs being tested for kidney cancer, including one from the hot field of immuno-oncology, proved superior in separate studies to a current standard treatment, setting the stage for new options for patients with an advanced stage of the disease. In one of the studies, researchers said patients taking Bristol-Myers Squibb Co. ’s Opdivo had …

View Post

Exelixis Drug Slows Kidney Cancer In New Chance For Embattled Biotech

In In The News by Barbara Jacoby

By: Matthew Herper From: forbes.com Update: This morning, Bristol-Myers Squibb announced that its immunotherapy, Opdivo, also delayed cancer progression more than Afinitor in kidney cancer. This raises questions about the sales potential of Exelixis’ drug. On September 2, 2014, shares in Exelixis, a drug maker that has spent two decades trying to turn the early fruits of genetic research into …

View Post

Looking for answers in cancer’s “exceptional responders”

In In The News by Barbara Jacoby

By: Brady Dennis From: washingtonpost.com Grace Silva and Karen Coakley are both 59, mothers living in the Boston suburbs and patients at Dana-Farber Cancer Institute, where they have spent years wrestling with daunting diagnoses. While they have never met, the two women are connected in a way that goes beyond their similar stories and their struggles with cancer. They share …

View Post

Biomarkers in urine may help detect kidney cancer early, study finds

In In The News by Barbara Jacoby

From: foxnews.com More than 80 percent of patients whose kidney cancer isn’t discovered until after it has spread will die within five years, and current tests for the disease are dependent on whether a patient has started showing symptoms. But a study published Thursday in the journal JAMA Oncology shows that  measuring protein levels in urine may help doctors identify …

Biotech Makes Personalized Cancer Vaccines Using Tumor Samples

In In The News by Barbara Jacoby

By: Susan Young Rojahn From: technologyreview.com A highly personalized medical technique is allowing patients with advanced kidney cancer to live nearly three times as long as they normally do. In an experiment involving 21 patients, around half lived more than two and half years after diagnosis with kidney cancer that had begun to spread. Five patients are alive after more …

New Drug May Help Immune System Fight Cancer

In In The News by Barbara Jacoby

An experimental drug that taps the power of the body’s immune system to fight cancer is shrinking tumors in patients for whom other treatments have failed, an early study shows. The drug binds to a protein called PD-L1 that sits on the surface of cancer cells and makes them invisible to the immune system, almost like a cloaking device. “That …